The significant drop in sales for Lyell Immunopharma is likely to negatively impact investor sentiment and the stock price in the short term. A 95.38% decrease in sales year-over-year is a substantial decline, indicating potential challenges in the company's operations or market demand for its products. This level of decrease is typically seen unfavorably by the market, leading to potential declines in stock price as investors reassess the company's growth prospects.